Kameka Hart
Psychiatric/Mental Health · Newark, DENPI 1528611662
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 76.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $7,635 and has fallen 91.2% since, to $671 in 2025. Among psychiatric/mental health clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $82.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$8K
- Neurocrine Biosciences, Inc.$646
- Johnson & Johnson$553
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$348
- Otsuka America Pharmaceutical, Inc.$241
- Teva Pharmaceuticals USA, Inc.$219
- plus $383 from 8 others
What the payments were for
- Speaking & faculty fees$5,61056%
- Travel & lodging$1,33313%
- Food & beverage$3,06631%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 28 | $7,646 |
| Neurocrine Biosciences, Inc. | 25 | $646 |
| Johnson & Johnson(2 entities) | 18 | $553 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 18 | $348 |
| Otsuka America Pharmaceutical, Inc. | 9 | $241 |
| Teva Pharmaceuticals USA, Inc. | 5 | $219 |
| E.r. Squibb & Sons, L.L.C. | 4 | $106 |
| Sunovion Pharmaceuticals Inc. | 5 | $85 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Lundbeck LLC | 2 | $46 |
| Indivior Inc. | 2 | $39 |
| AbbVie | 1 | $29 |
| Braeburn Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$29,050
- ARISTADA INITIO$7,263
- INGREZZA$125
- INVEGA SUSTENNA$114
- CAPLYTA$111
How this compares
$10,036 in reported general payments places this provider in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 147 | $484,463 |
| IngrezzaValbenazine Tosylate | 37 | $304,159 |
| Abilify MaintenaAripiprazole | 40 | $116,444 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 14 | $58,918 |
| CaplytaLumateperone Tosylate | 33 | $56,932 |
| AristadaAripiprazole Lauroxil | 12 | $43,414 |
| Chlorpromazine Hcl | 96 | $27,134 |
| JardianceEmpagliflozin | 45 | $26,654 |
| JanuviaSitagliptin Phosphate | 35 | $19,100 |
| RexultiBrexpiprazole | 14 | $18,949 |
| Acitretin | 12 | $16,204 |
| Divalproex Sodium ErDivalproex Sodium | 235 | $15,358 |
| Lurasidone Hcl | 69 | $12,302 |
| TradjentaLinagliptin | 23 | $11,690 |
| Fluphenazine Hcl | 38 | $9,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $553 | $484,463147 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $646 | $304,15937 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $241 | $135,39354 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $348 | $56,93233 claims |
| Alkermes, Inc.Aristada | $7,646 | $43,41412 claims |
| AbbVieLinzess | $29 | $7,30414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 177 psychiatric/mental health providers in Delaware.
Other psychiatric/mental health in Newark
- Bradley WhyNewark$6K
- Ema SohnaNewark$5K
- Kareemah HammondNewark$4K
- Tiffany DysonNewark$3K
- Bernadette MomohNewark$3K
- Stefanie FerraroNewark$2K
- Catherine LukoNewark$2K
- Ronald TyreeWilmington$59K
- Ericka Taylor-DanielDover$39K
- Cindy CunninghamDover$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.